Clopidogrel은 항혈소판제로 여러 임상영역에서 사용된다. 기존의 약제보다 부작용도 적어 안전하게 널리 쓸 수 있는 이 약제가 드물게는 이와 같은 심각한 합병증을 유발할 수 있다. 이에 우리...
http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
https://www.riss.kr/link?id=A82594426
2011
Korean
513
KCI등재
학술저널
253-257(5쪽)
0
0
상세조회0
다운로드국문 초록 (Abstract)
Clopidogrel은 항혈소판제로 여러 임상영역에서 사용된다. 기존의 약제보다 부작용도 적어 안전하게 널리 쓸 수 있는 이 약제가 드물게는 이와 같은 심각한 합병증을 유발할 수 있다. 이에 우리...
Clopidogrel은 항혈소판제로 여러 임상영역에서 사용된다. 기존의 약제보다 부작용도 적어 안전하게 널리 쓸 수 있는 이 약제가 드물게는 이와 같은 심각한 합병증을 유발할 수 있다. 이에 우리는 이러한 합병증을 이해하고 주의 해야 한다. 저자들은 급성 관상동맥 증후군이 있었던 47세 남자 환자에서 이와 같은 합병증을 경험하였고, 약물 중단 및 치료적 혈장분리술 등으로 호전되었던 증례를 1예 경험하였기에 문헌고찰과 함께 보고하는 바이다.
다국어 초록 (Multilingual Abstract)
Thienopyridines are antiplatelet agents used in post-percutaneous coronary angioplasty patients and patients with acute coronary syndrome, stroke, and peripheral arterial disease. Ticlopidine has been shown to reduce the incidence of stent thrombosis,...
Thienopyridines are antiplatelet agents used in post-percutaneous coronary angioplasty patients and patients with acute coronary syndrome, stroke, and peripheral arterial disease. Ticlopidine has been shown to reduce the incidence of stent thrombosis, but it may also cause serious hematological side effects. Among the thienopyridines, clopidogrel is considered to be a safe alternative to ticlopidine because of its decreased incidence of hematological adverse effects. However, some hematological side effects can occur and may be fatal. In this case, a 47-year-old man complained of dyspnea and generalized edema. He had been taking clopidogrel after coronary angioplasty. His laboratory findings showed acute renal failure, microangiopathic hemolytic anemia, and thrombocytopenia, which were consistent with hemolytic uremic syndrome (HUS). After discontinuing clopidogrel and undergoing plasma exchange, he recovered fully. To our knowledge, this is the first reported case of clopidogrel-induced HUS in Korea. (Korean J Med 2011;80:S253-S257)
참고문헌 (Reference)
1 Amorosi EL, "Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature" 45 : 139-160, 1966
2 Bennett CL, "Thrombotic thrombocytopenic purpura associated with clopidogrel" 342 : 1773-1777, 2000
3 Mehta SR, "The clopidogrel in unstable angina to prevent recurrent events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease" 21 : 2033-2041, 2000
4 Gasser C, "Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia" 85 : 905-909, 1955
5 Balamuthusamy S, "Hematologic adverse effects of clopidogrel" 14 : 106-112, 2007
6 Steinhubl SR, "Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial" 288 : 2411-2420, 2002
7 Bertrand ME, "Doubleblind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS)" 102 : 624-629, 2000
8 Majhail NS, "Clopidogrel and thrombotic thrombocytopenic purpura: no clear case for causality" 70 : 466-470, 2003
9 Herbert JM, "Biochemical and pharmacological properties of clopidogrel: a new ADP receptor antagonist" 1 : A31-A40, 1999
10 Diener HC, "Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial" 364 : 331-337, 2004
1 Amorosi EL, "Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature" 45 : 139-160, 1966
2 Bennett CL, "Thrombotic thrombocytopenic purpura associated with clopidogrel" 342 : 1773-1777, 2000
3 Mehta SR, "The clopidogrel in unstable angina to prevent recurrent events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease" 21 : 2033-2041, 2000
4 Gasser C, "Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia" 85 : 905-909, 1955
5 Balamuthusamy S, "Hematologic adverse effects of clopidogrel" 14 : 106-112, 2007
6 Steinhubl SR, "Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial" 288 : 2411-2420, 2002
7 Bertrand ME, "Doubleblind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS)" 102 : 624-629, 2000
8 Majhail NS, "Clopidogrel and thrombotic thrombocytopenic purpura: no clear case for causality" 70 : 466-470, 2003
9 Herbert JM, "Biochemical and pharmacological properties of clopidogrel: a new ADP receptor antagonist" 1 : A31-A40, 1999
10 Diener HC, "Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial" 364 : 331-337, 2004
11 Sabatine MS, "Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation" 352 : 1179-1189, 2005
12 CAPRIE steering committee, "A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) CAPRIE Steering Committee" 348 : 1329-1339, 1996
증례 : 신장 ; 이뇨제 복용 중 소량의 감초 복용 후 발생한 저칼륨혈증성 횡문근 융해증 1예
증례 : 신장 ; 급성 신부전과 흉수를 동반한 원발성 후복막강 섬유화증 1예
증례 : 혈액종양 ; De novo t(11:19) 염색체 전위를 보인 급성전골수성백혈병 1예
증례 : 혈액종양 ; 임신과 동반된 원발성 종격동 거대 B세포 림프종에서 Rituximab 치료
학술지 이력
연월일 | 이력구분 | 이력상세 | 등재구분 |
---|---|---|---|
2023 | 평가예정 | 계속평가 신청대상 (계속평가) | |
2021-01-01 | 평가 | 등재후보학술지 선정 (신규평가) | ![]() |
2018-12-01 | 평가 | 등재후보 탈락 (계속평가) | |
2017-12-01 | 평가 | 등재후보로 하락 (계속평가) | ![]() |
2013-01-01 | 평가 | 등재학술지 유지 (등재유지) | ![]() |
2010-01-01 | 평가 | 등재학술지 유지 (등재유지) | ![]() |
2008-01-01 | 평가 | 등재학술지 유지 (등재유지) | ![]() |
2006-05-15 | 학술지명변경 | 외국어명 : Korean Journal of Medicine -> The Korean Journal of Medicine | ![]() |
2006-01-01 | 평가 | 등재학술지 유지 (등재유지) | ![]() |
2003-01-01 | 평가 | 등재학술지 선정 (등재후보2차) | ![]() |
2002-01-01 | 평가 | 등재후보 1차 PASS (등재후보1차) | ![]() |
2000-07-01 | 평가 | 등재후보학술지 선정 (신규평가) | ![]() |
학술지 인용정보
기준연도 | WOS-KCI 통합IF(2년) | KCIF(2년) | KCIF(3년) |
---|---|---|---|
2016 | 0.1 | 0.1 | 0.1 |
KCIF(4년) | KCIF(5년) | 중심성지수(3년) | 즉시성지수 |
0.11 | 0.1 | 0.259 | 0.02 |